Analyzing patient‐reported outcome data when completion differs between arms in open‐label trials: an application of principal stratification. Issue 10 (13th August 2019)
- Record Type:
- Journal Article
- Title:
- Analyzing patient‐reported outcome data when completion differs between arms in open‐label trials: an application of principal stratification. Issue 10 (13th August 2019)
- Main Title:
- Analyzing patient‐reported outcome data when completion differs between arms in open‐label trials: an application of principal stratification
- Authors:
- Roydhouse, Jessica K.
Gutman, Roee
Bhatnagar, Vishal
Kluetz, Paul G.
Sridhara, Rajeshwari
Mishra‐Kalyani, Pallavi S. - Abstract:
- Abstract: Purpose: Cancer trials are often open‐label and include patient‐reported outcomes (PROs). Previous work has demonstrated that patients may complete PRO assessments less frequently in the control arm compared with the experimental arm in open‐label trials. Such differential completion may affect PRO results. This paper sought to explore principal stratification methodology to address potential bias caused by the posttreatment intermediate variable of questionnaire completion. Methods: We evaluated six randomized trials (five open‐label and one double‐blind) of anticancer therapies with varying levels of PRO completion submitted to the Food and Drug Administration (FDA). We applied complete case analysis (CCA), multiple imputation (MI), and principal stratification to evaluate PRO results for quality of life (QOL) and the domains of physical, role, and emotional function (PF, RF, and EF). Assignment to potential principal strata was by the expectation maximization algorithm using patient baseline characteristics. Results: Completion rates in the experimental arm ranged from 66% to 94% and 51% to 95% in the control arm. Four trials had negligible completion differences between arms (1%‐2%), and two had large differences favoring the experimental arm (15%‐17%). For trials with negligible completion differences, principal stratification results were similar to CCA and MI results for all domains. Notable differences in point estimates may be observed in trials with largeAbstract: Purpose: Cancer trials are often open‐label and include patient‐reported outcomes (PROs). Previous work has demonstrated that patients may complete PRO assessments less frequently in the control arm compared with the experimental arm in open‐label trials. Such differential completion may affect PRO results. This paper sought to explore principal stratification methodology to address potential bias caused by the posttreatment intermediate variable of questionnaire completion. Methods: We evaluated six randomized trials (five open‐label and one double‐blind) of anticancer therapies with varying levels of PRO completion submitted to the Food and Drug Administration (FDA). We applied complete case analysis (CCA), multiple imputation (MI), and principal stratification to evaluate PRO results for quality of life (QOL) and the domains of physical, role, and emotional function (PF, RF, and EF). Assignment to potential principal strata was by the expectation maximization algorithm using patient baseline characteristics. Results: Completion rates in the experimental arm ranged from 66% to 94% and 51% to 95% in the control arm. Four trials had negligible completion differences between arms (1%‐2%), and two had large differences favoring the experimental arm (15%‐17%). For trials with negligible completion differences, principal stratification results were similar to CCA and MI results for all domains. Notable differences in point estimates may be observed in trials with large differences in completion rates. However, in the examined trials, the confidence intervals for the principal stratification estimates overlapped with the ones obtained using CCA. Conclusions: The principal stratification estimand may be a useful additional analysis, especially if PRO completion differs between arms. … (more)
- Is Part Of:
- Pharmacoepidemiology and drug safety. Volume 28:Issue 10(2019)
- Journal:
- Pharmacoepidemiology and drug safety
- Issue:
- Volume 28:Issue 10(2019)
- Issue Display:
- Volume 28, Issue 10 (2019)
- Year:
- 2019
- Volume:
- 28
- Issue:
- 10
- Issue Sort Value:
- 2019-0028-0010-0000
- Page Start:
- 1386
- Page End:
- 1394
- Publication Date:
- 2019-08-13
- Subjects:
- cancer -- causal inference -- function -- open‐label -- patient‐reported outcome -- pharmacoepidemiology -- principal stratification -- quality of life -- randomized controlled trial
Pharmacoepidemiology -- Periodicals
Chemotherapy -- Periodicals
Epidemiology -- Periodicals
615.705 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1002/pds.4875 ↗
- Languages:
- English
- ISSNs:
- 1053-8569
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6446.248000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 17474.xml